Cadre Holdings (CDRE) Q1 2026 earnings review
Record Backlog and Top-Line Growth Mask Heavy Margin Dilution
Cadre kicked off 2026 with a massive 19% YoY revenue increase to $155.4M and a record backlog of $355M. However, the bottom line tells a drastically different story. Net Income plummeted 78% YoY to $2.0M, pressured by M&A integration costs, a $2.6M inventory step-up amortization, and elevated interest expenses from debt-funded acquisitions. Gross margins deteriorated significantly, dropping 440 basis points YoY to 38.7%. While management's aggressive M&A strategy (deploying over $400M since Jan 2024) is driving undeniable volume growth and backlog visibility, the near-term earnings quality has severely degraded. Full-year guidance was reaffirmed, implying a belief that these margin compressions are transient, but execution risk remains exceptionally high as leverage climbs.
🐂 Bull Case
Total backlog nearly doubled sequentially to $355M. Organic backlog alone increased by $108M from Q4 to Q1, driven by multi-year defense awards like the GDELS blast seat contract, practically locking in future revenue.
Cadre is rapidly scaling. The TYR Tactical and Alien Gear Holsters acquisitions expand Cadre's hard armor capabilities and direct-to-consumer reach, positioning the company to capture broader market share globally.
🐻 Bear Case
Gross margin dropped 440 bps YoY to 38.7%, and Adjusted EBITDA margin contracted to 13.6% from 15.8%. If the company cannot cycle through acquisition accounting impacts and unfavorable product mix quickly, profitability will structurally decline.
Net debt surged to $324.6M (2.9x LTM Adjusted EBITDA), up from $184.4M just a quarter prior. The rapid pace of debt-funded M&A leaves less room for error in a higher-for-longer interest rate environment.
⚖️ Verdict: ⚪
Neutral. The top-line momentum and backlog growth are undeniably impressive and secure long-term stability. However, the sheer magnitude of margin compression and the 78% drop in net income demand caution until the newly acquired assets prove accretive to the bottom line.
Key Themes
Record Backlog Secured by Mega-Contracts
The company's backlog trajectory is violently accelerating, reaching a record $355M (up $166M sequentially). A massive driver is the $86.4M GDELS contract for Med-Eng blast attenuation seats. Production begins in 2026 with full-scale deliveries in 2027, securing a highly visible, multi-year revenue stream.
Relentless M&A Engine Execution
Management continues to utilize acquisitions as its primary growth lever, deploying over $400M since Jan 2024. The Q1 integration of TYR Tactical adds advanced 7,000-ton armor pressing capabilities and international military exposure. The April acquisition of Alien Gear Holsters ($10.3M purchase price) instantly establishes a direct-to-consumer footprint in the civilian and law enforcement holster market.
Geopolitical and Public Safety Tailwinds
Cadre is directly benefiting from elevated global defense spending and heightened geopolitical tensions. The macro backdrop remains highly constructive for Cadre's core mission-critical safety products, insulating the top line from broader consumer economic cycles.
Gross Margin Reversal Contradicts Top-Line Narrative
Despite management touting 'significant momentum,' actual profitability is reversing. Total gross margin plunged from 43.1% in 25Q1 to 38.7% in 26Q1. This 440 bps collapse was driven by $2.6M in inventory step-up amortization from the TYR acquisition and an unfavorable product mix skewed toward lower-margin distribution and specific armor segments.
Deteriorating Leverage Profile
The balance sheet is absorbing heavy blows from the M&A spree. Total debt increased by $58.5M in a single quarter, pushing Net Debt to $324.6M. Consequently, Net Debt to LTM Adjusted EBITDA climbed to 2.9x, significantly eroding the financial flexibility management frequently highlights.
Nuclear Segment Mix Headwinds
The suspension of the government's plutonium downblending program continues to act as a near-term margin headwind. While management expects commercial nuclear growth to eventually offset this, the immediate result is a loss of high-margin Alpha safety product volume, creating a negative mix effect that is actively pressuring 2026 profitability.
Other KPIs
Decelerating margin. While absolute Adjusted EBITDA grew 3% YoY (from $20.5M), the margin compressed significantly from 15.8% to 13.6%. The company is generating more revenue but keeping less of it, highlighting the dilutive impact of recent acquisitions before synergies are realized.
Reversing sharply from 44.4% in the prior year period. The core product segment, which historically drives Cadre's profitability, suffered heavily from acquisition accounting (inventory step-ups) and unfavorable mix. This validates that the volume growth from M&A currently comes at the expense of margin quality.
Accelerating from $17.4M in Q1 2025. Despite the collapse in net income, cash generation remains robust, primarily aided by non-cash add-backs (depreciation, amortization, stock-based compensation) and a favorable $13.5M swing in accounts payable. Cash flow is the lone bright spot in an otherwise messy income statement.
Guidance
Accelerating. The midpoint of $747M implies a robust 22.4% YoY growth compared to FY 2025 ($610.3M). This aggressive top-line trajectory is heavily supported by the TYR Tactical acquisition and the record $355M backlog.
Accelerating in absolute terms, but implying margin stagnation. The midpoint of $138.5M represents 24% YoY growth. However, this implies a full-year Adjusted EBITDA margin of roughly 18.5%, effectively flat compared to the 18.3% achieved in FY 2025, indicating that management does not expect significant margin expansion this year despite vast scale increases.
Accelerating investment. The midpoint of $12M is a notable step up from historical levels (e.g., $6.8M in FY 2025), driven by capacity expansion requirements and facility buildouts specifically targeting the newly acquired nuclear operations.
Key Questions
Bridge to Margin Normalization
Gross margins compressed by 440 bps this quarter largely due to inventory step-ups and mix. What is the precise timeline for these accounting headwinds to roll off, and what is the normalized gross margin profile of the combined entity heading into 2027?
Leverage and M&A Appetite
With Net Debt to Adjusted EBITDA approaching 3.0x, has the company reached its maximum comfort level for leverage? Does this signal a pause in the M&A strategy to focus purely on debt paydown and integration?
Nuclear Offset Visibility
You noted that the suspension of plutonium downblending is a near-term drag on high-margin Alpha products. How quickly can the commercial nuclear funnel convert to revenues to actively plug this high-margin gap?